세계의 블루 바이오테크놀러지 시장 : 제품별, 용도별, 최종사용자별, 지역별 예측(-2032년)

Global Blue Biotechnology Market Research Report Information by Product, by Application, and by End User and by Region - Forecast till 2032

US $ 4,950 ￦ 6,934,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 5,950 ￦ 8,335,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 7,250 ￦ 10,156,000

PDF & Excel (Enterprise License)

PDF, Excel 보고서를 동일 기업이 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능하며, 인쇄 가능합니다.

한글목차

블루 바이오테크놀러지 시장 규모는 2024년 56억 5,000만 달러에서 예측 기간 동안 복합 연간 성장률(CAGR) 7.15%로 추이되며, 2032년에는 105억 4,000만 달러 규모에 달할 것으로 예측됩니다. 해양 생물 유래의 의약품이나 영양 보조 식품에 관한 전략적 이니셔티브나, 블루 바이오테크놀러지에 근거한 영양 보조 식품이나 의약품에 대한 의식의 고조등의 요인이 동 시장의 성장을 견인하고 있습니다.

블루 바이오테크놀러지에 기반한 영양보조식품과 의약품에 대한 의식 증가는 이 시장의 성장의 중요한 요인입니다. 해양 유래 물질의 건강 효과에 대한 소비자의 인식이 높아지는 가운데, 해양 생물 유래의 것에 대한 수요가 높아지고 있습니다. 오메가 3 지방산, 항산화 물질, 미네랄 등의 해양 성분을 포함한 영양 보충제는 건강상의 이점으로부터 인기가 높아지고 있습니다.

지역별 인사이트력

북미는 R&D 활동에 대한 투자 증가, 의료 인프라 개선, 이 지역에서 확립된 의약품 제조업체의 존재로 인해 2023년에 약 36.04%에서 가장 큰 시장 점유율을 보였습니다.

유럽 시장은 수많은 신흥 기업의 존재로 예측 기간 동안 크게 확대될 것으로 예상됩니다.

아시아태평양 시장은 농업, 의약품, 화장품 등 산업에서 해양 유래 제품에 대한 수요가 증가함에 따라 예측 기간 동안 가장 빠르게 발전할 것으로 예상됩니다. 또한 유전체학, 단백질체학, 대사체학 등 바이오테크놀러지의 툴과 기술의 향상으로 해양자원의 연구와 이용이 용이해지고 시장의 성장이 높아지고 있습니다. 이러한 기술을 통해 연구자들은 해양 자원에서 중요한 화학물질을 보다 효율적으로 검출, 분리, 추출할 수 있습니다.

이 보고서는 세계의 블루 바이오 기술 시장을 조사했으며, 시장 정의 및 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추이 및 예측, 각종 구분 및 지역별 분석, 경쟁 환경, 주요 기업 프로파일 등을 정리했습니다.

목차

제1장 주요 요약

제2장 시장 개요

제3장 조사 방법

제4장 시장 역학

• 성장 촉진요인
  • 블루 바이오테크놀러지에 기초한 영양 보조 식품과 의약품의 인지도의 향상
  • 해양 생물 유래의 의약품이나 영양 보조 식품에 관련하는 전략적 이니셔티브 증가
• 억제요인
  • 엄격한 규제 정책
• 기회
  • 생명공학 기반의 의약품 개발 투자 증가

제5장 시장 요인 분석

• Porter's Five Forces 분석
• COVID-19의 영향

제6장 세계의 블루 바이오테크놀러지 시장 : 제품별

• 개요
• 효소
• 의약품
• 벌크케미칼
• 바이오폴리머
• 기타

제7장 세계의 블루 바이오테크놀러지 시장 : 용도별

• 개요
• 바이오엔지니어링
• 유전체학
• 백신 개발
• 창약
• 어업
• 양식업
• 바이오연료
• 수처리 서비스
• 기타

제8장 세계의 블루 바이오 기술 시장 : 최종 사용자별

• 개요
• 병원
• 제약회사
• 바이오테크놀러지 기업
• 기타

제9장 세계의 블루 바이오 기술 시장 : 지역별

• 세계의
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제10장 경쟁 구도

• 개요
• 경쟁 벤치마킹
• 주요 성장 전략
• 개발 건수로 톱의 기업
• 주요 개발 분석
• 주요 전개와 성장 전략
• 주요 기업의 재무 동향

제11장 기업 프로파일

• MARINOMED BIOTECH AG
• MARSHALL MARINE PRODUCTS/
• MARINOVA
• AKER BIOMARINE
• PHARMAMAR
• CYANOTECH CORPORATION
• ADM
• GEOMARINE BIOTECHNOLOGIES
• CP KELCO US, INC.
• TERSERA THERAPEUTICS LLC

제12장 부록

BJH

영문 목차

영문목차

Global Blue Biotechnology Market Research Report Information by Product (Enzymes, Pharma Products, Bulk Chemicals, and Others), by Application (Bioengineering, Genomics, Vaccine Development, Drug Discovery, Fisheries, Aquaculture, Biofuels, Water Treatment Services, and Others), and by End User (Hospitals, Pharmaceutical Companies, Biotechnology Companies, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview

The Blue Biotechnology Market is expected to increase from USD 5.65 billion in 2024 to USD 10.54 billion by 2032, with a compound annual growth rate (CAGR) of 7.15% over the forecast period (2024-2032). The global market is being driven by increased awareness of blue biotechnology-based nutraceuticals and pharmaceuticals, as well as strategic initiatives involving medicines and nutraceuticals derived from marine creatures.

The growing awareness of blue biotechnology-based nutraceuticals and medicines is a key factor driving the blue biotechnology industry forward. As consumers become more aware of the health benefits of marine-derived substances, there is an increasing demand for items derived from marine species. Nutraceuticals containing marine components, such as omega-3 fatty acids, antioxidants, and minerals, are becoming increasingly popular due to their supposed health benefits.

Furthermore, a surge in strategic activities aiming at pharmaceutical and nutraceutical goods generated from marine organisms is propelling the Blue Biotechnology Market. As the pharmaceutical and nutraceutical companies seek new ways to address increasing healthcare and dietary demands, their attention has switched to the ocean's immense and largely unexplored resources.

Market Segment insights

The Blue Biotechnology Market is divided into several product categories, including enzymes, pharmaceuticals, bulk chemicals, biopolymers, and others.

The Blue Biotechnology Market is divided into several types, including bioengineering, genomics, vaccine development, drug research, fisheries, aquaculture, biofuels, water treatment services, and others.

The blue biotechnology market is divided into four end user segments: hospitals, pharmaceutical firms, biotechnology businesses, and others.

Regional insights

The market is segmented into four regions: North America, Europe, Asia-Pacific, and the rest of the world. North America had the biggest market share of approximately 36.04% in 2023, owing to increased investment in R&D activities, improved healthcare infrastructure, and the presence of established medication manufacturers in the region. Furthermore, the presence of well-known industry players who are actively involved in meeting consumer demand in the region is boosting the market's growth.

The European blue biotechnology market is expected to increase significantly during the forecast year, 2024-2032, due to the existence of numerous blue biotechnology start-ups. For example, the Calouste Gulbenkian and Oceano Azul Foundations, both based in Portugal, have received more than 120 blue biotechnology-related proposals from over 30 countries through September 2020.

The Asia-Pacific blue biotechnology market is expected to develop the quickest over the forecast period, driven by rising demand for marine-derived goods in industries such as agriculture, medicines, and cosmetics. Furthermore, improvements in biotechnological tools and techniques such as genomics, proteomics, and metabolomics have made it easier to research and use marine resources, resulting in increased market growth. These methods enable researchers to more efficiently detect, isolate, and extract important chemicals from marine species.

Major Players

Marinomed Biotech AG (Austria), Marshall Marine Products (India), Marinova (Australia), Aker BioMarine (Norway), Pharma Mar (Spain), Cyanotech Corporation (US), ADM (US), Geomarine (India), CP Kelco U.S., Inc. (US), and TerSera Therapeutics LLC (US) are among the key players in the Blue Biotechnology Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING AWARENESS OF BLUE BIOTECHNOLOGY-BASED NUTRACEUTICALS AND PHARMACEUTICALS
  • 4.2.2 RISING STRATEGIC INITIATIVES ASSOCIATED WITH PHARMACEUTICALS AND NUTRACEUTICALS SOURCED FROM MARINE ORGANISMS
• 4.3 RESTRAINTS
  • 4.3.1 STRINGENT REGULATORY POLICIES
• 4.4 OPPORTUNITIES
  • 4.4.1 INCREASING INVESTMENT IN THE DEVELOPMENT OF BIOTECHNOLOGY-BASED MEDICINE

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON THE INDIA CELL CULTURE MEDIA MARKET
  • 5.2.1 IMPACT ON SUPPLY CHAIN

6 GLOBAL BLUE BIOTECHNOLOGY MARKET, BY PRODUCT

• 6.1 OVERVIEW
• 6.2 ENZYMES
• 6.3 PHARMA PRODUCTS
• 6.4 BULK CHEMICALS
• 6.5 BIOPOLYMERS
• 6.6 OTHERS

7 GLOBAL BLUE BIOTECHNOLOGY MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 BIOENGINEERING
• 7.3 GENOMICS
• 7.4 VACCINE DEVELOPMENT
• 7.5 DRUG DISCOVERY
• 7.6 FISHERIES
• 7.7 AQUACULTURE
• 7.8 BIOFUELS
• 7.9 WATER TREATMENT SERVICES
• 7.10 OTHERS

8 GLOBAL BLUE BIOTECHNOLOGY MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 HOSPITALS
• 8.3 PHARMACEUTICAL COMPANIES
• 8.4 BIOTECHNOLOGY COMPANIES
• 8.5 OTHERS

9 GLOBAL BLUE BIOTECHNOLOGY MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 NORWAY
  • 9.3.7 NETHERLANDS
  • 9.3.8 SWITZERLAND
  • 9.3.9 FINLAND
  • 9.3.10 BELGIUM
  • 9.3.11 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 LATIN AMERICA
  • 9.5.2 MIDDLE EAST
  • 9.5.3 AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 MAJOR GROWTH STRATEGY IN THE BLUE BIOTECHNOLOGY MARKET
• 10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE BLUE BIOTECHNOLOGY MARKET
• 10.5 KEY DEVELOPMENT ANALYSIS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
  • 10.6.2 AGREEMENT
  • 10.6.3 PARTNERSHIP
  • 10.6.4 ACQUISITION
• 10.7 MAJOR PLAYERS FINANCIAL
  • 10.7.1 SALES (USD MILLION),
  • 10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION),

11 COMPANY PROFILES

• 11.1 MARINOMED BIOTECH AG
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 KEY STRATEGIES
• 11.2 MARSHALL MARINE PRODUCTS/
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 KEY STRATEGIES
• 11.3 MARINOVA
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 AKER BIOMARINE
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGIES
• 11.5 PHARMAMAR
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 SWOT ANALYSIS
  • 11.5.6 KEY STRATEGIES
• 11.6 CYANOTECH CORPORATION
  • 11.6.1 COMPANY OVERVIEWS
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGIES
• 11.7 ADM
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL ANALYSIS
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGIES
• 11.8 GEOMARINE BIOTECHNOLOGIES
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 KEY STRATEGIES
• 11.9 CP KELCO U.S., INC.
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCT OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 TERSERA THERAPEUTICS LLC
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 SWOT ANALYSIS
  • 11.10.6 KEY STRATEGIES

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS

관련자료